Russia’s direct investment fund announced tonight (Wednesday) an interim trial that will combine the technology of developing the Russian vaccine against corona, Sputnik 5, and the development of the British vaccine, Astraznanyka. Its results are expected to crystallize in about two months.
The fund’s CEO, Kirill Dmitriev, who is also in charge of marketing the Russian vaccine worldwide, has announced that the trial will begin next week, and will be held in the UAE.
Volunteers receive the vaccine in Russia. Photo: Reuters
As you may recall, about three weeks ago, the European Medicines Agency (EMA) announced that it would start testing the effectiveness of the Russian vaccine against corona. If approved, EU countries will be the first Western countries to use the vaccine.
The vaccine, developed and manufactured in Russia, has so far been distributed in many countries around the world, including Argentina and other countries in South America, Southeast Asia, Eastern Europe and even the Gaza Strip.
In contrast, the Astrazenica vaccine has recently been tested once again, due to reports of recent symptoms in Europe, related to blood clots formed after the second vaccine. However, the reported incidents have not yet been proven to be a direct product of the vaccine.